Relação da infecção por Sars-Cov-2 e incidência de eventos cardiovasculares
Relationship of Sars-Cov-2 infection and incidence of cardiovascular events
DOI:
https://doi.org/10.34119/bjhrv5n6-064Keywords:
COVID-19, Síndrome Coronariana Aguda, circulatórioAbstract
A COVID-19 é uma doença causada pelo SaRS-CoV-2 e surgiu em Wuhan, na China, no final de 2019. No ano seguinte a Organização Mundial de saúde decretou um estado de pandemia, devido aos efeitos e à expansibilidade do vírus. Além do sistema respiratório, com o tempo a patologia foi mostrando diversos sintomas relacionados com os diversos sistemas do corpo humano e a forma com a qual os afetava negativamente. Entre estes sistemas, logo inicialmente foi notado os seus efeitos no sistema cardiovascular e em eventos circulatórios e cardíacos. Somado a isso, entendemos que, o envolvimento desses sintomas aumenta o risco de fatalidade devido à doença e suas complicações, precisando ser discutido e compreendido o mecanismo fisiopatológico. O objetivo deste trabalho cursa com o entendimento dos diversos sintomas cardíacos, derivados da relação entre o SARS-CoV-2 e a enzima conversora de angiotensina 2 (ECA2), sua porta de entrada para as células humanas, para finalmente esclarecer se a infecção causadora do COVID-19 aumenta ou não a incidência de eventos cardiovasculares. Para tal, foram analisados 22 artigos que tratavam acerca do tema, e após compilados e analisados os seus resultados, concluindo que a síndrome deve ser acompanhada de perto em pacientes com sintomas iniciais de acometimento cardíaco uma vez que isto pode evoluir rapidamente para problemas irreversíveis.
References
BALDI E. Out-of-hospital cardiac arrest during the COVID-19 outbreak in Italy. N. Engl. J. Med. 2020;383:496–498
BHATT A.S., Moscone A., McElrath E.E., et al. Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic. J. Am. Coll. Cardiol. 2020;76(3):280–288
DOU Q, WEI X, ZHOU K, YANG S, JIA P. Cardiovascular Manifestations and Mechanisms in Patients with COVID-19. Trends Endocrinol Metab. 2020 Dec;31(12):893-904. doi: 10.1016/j.tem.2020.10.001. Epub 2020 Oct 16. PMID: 33172748; PMCID: PMC7566786.
GOYAL P. Clinical characteristics of COVID-19 in New York City. N. Engl. J. Med. 2020;382:2372–2374.
GUO T., FAN Y., CHEN M., et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020 Jul 1;5(7):811
GUZIK T.J., MOHIDDIN S.A., DIMARCO A., et al. 2020 Apr 30. COVID-19 and the
cardiovascular system: implications for risk assessment, diagnosis, and treatment options. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197627/ Cardiovasc Res [Internet]
HELMS J. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089–1098.
HUANG C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
JABRI A. Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic. JAMA Netw. Open. 2020;3.
KAYE AD, SPENCE AL, MAYERLE M, SARDANA N, CLAY CM, ENG MR, LUEDI MM,
CARROLL Turpin MA, URMAN RD, CORNETT EM. Impact of COVID-19 infection on the cardiovascular system: An evidence-based analysis of risk factors and outcomes. Best Pract Res Clin Anaesthesiol. 2021 Oct;35(3):437-448. doi: 10.1016/j.bpa.2021.02.003. Epub 2021 Mar 1. PMID: 34511231; PMCID: PMC7919539.
KUNUTSOR S.K., LAUKKANEN J.A. Cardiovascular complications in COVID-19: a systematic review and meta-analysis. J Infect. 2020 Aug;81(2):e139–e141.
LEE S.G., FRALICK M., SHOLZBERG M. Coagulopathy associated with COVID-19. Can Med Assoc J. 2020 May 25;192(21):E583. E583.
LIPPI G., PLEBANI M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med CCLM. 2020 Jun 25;58(7):1131–1134
LIU H. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. Cardiovasc. Res. 2020;116:1733–1741
LLITJOS J.F. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J. Thromb. Haemost. 2020;18:1743–1746.
MADJID M., MILLER C.C., ZARUBAEV V.V., et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur. Heart J. 2007;28(10):1205–1210.
POISSY J. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142:184–186
PUNTMANN V.O. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020
RUAN Q. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–848
SALA S. Acute myocarditis presenting as a reverse Tako–Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur. Heart J. 2020;41:1861–1862
SATTAR Y., ULLAH W., RAUF H., et al. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. IJC Heart Vasc. 2020 Aug;29:100589 Sattar Y., Ullah W., Rauf H., et al. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. IJC Heart Vasc. 2020 Aug;29:100589
SOUMYA R.S., UNNI T.G., RAGHU K.G. Impact of COVID-19 on the cardiovascular system: a review of available reports. Cardiovasc Drugs Ther. 2020 Sep 14:1–15. doi: 10.1007/s10557-020-07073-y. http://link.springer.com/10.1007/s10557-020-07073-y
SHAO F. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020;151:18–23.
SHI S. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810.
TANG N., LI D., WANG X., et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemostasis. 2020 Apr;18(4):844–847.
TAVAZZI G. Myocardial localization of coronavirus in COVID-19 cardiogenic shock.
Europian Journal Heart Fail. 2020;22:911–915.
VAKHSHOORI M., HEIDARPOUR M., SHAFIE D., et al. Acute cardiac injury in COVID-19: a systematic review and meta-analysis. Arch Iran Med. 2020 Nov 1;23(11):801–812
WALTERS T.E. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace. 2017;19:1280–1287
WANG D., HU B., HU C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. J Am Med Assoc. 2020 Mar 17;323(11):1061.
WEI J.-F., HUANG F.-Y., XIONG T.-Y., et al. Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis. Heart. 2020 Aug;106(15):1154–159 Doyen D. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020;395:1516.
ZHOU F. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
ZHENG Y.-Y., MA Y.-T., ZHANG J.-Y., et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259–260.
